IRX Stock Overview
Engages in the developing and commercializing of medical drug delivery systems in Australia.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
InhaleRx Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.04 |
| 52 Week High | AU$0.05 |
| 52 Week Low | AU$0.02 |
| Beta | -0.74 |
| 1 Month Change | 29.03% |
| 3 Month Change | 5.26% |
| 1 Year Change | -11.11% |
| 3 Year Change | -57.89% |
| 5 Year Change | -46.67% |
| Change since IPO | -90.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| IRX | AU Medical Equipment | AU Market | |
|---|---|---|---|
| 7D | 0% | 2.2% | 0.7% |
| 1Y | -11.1% | 18.2% | 7.8% |
Return vs Industry: IRX underperformed the Australian Medical Equipment industry which returned 18.2% over the past year.
Return vs Market: IRX underperformed the Australian Market which returned 7.8% over the past year.
Price Volatility
| IRX volatility | |
|---|---|
| IRX Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 9.8% |
| Market Average Movement | 9.0% |
| 10% most volatile stocks in AU Market | 17.6% |
| 10% least volatile stocks in AU Market | 3.4% |
Stable Share Price: IRX's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine IRX's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | n/a | Darryl Davies | inhalerx.com.au |
InhaleRx Limited engages in the developing and commercializing of medical drug delivery systems in Australia. It also develops inhaled drug formulations. The company was formerly known as Lifespot Health Ltd and changed its name to InhaleRx Limited in October 2021.
InhaleRx Limited Fundamentals Summary
| IRX fundamental statistics | |
|---|---|
| Market cap | AU$7.59m |
| Earnings (TTM) | -AU$1.44m |
| Revenue (TTM) | AU$1.20m |
6.3x
P/S Ratio-5.3x
P/E RatioIs IRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IRX income statement (TTM) | |
|---|---|
| Revenue | AU$1.20m |
| Cost of Revenue | AU$0 |
| Gross Profit | AU$1.20m |
| Other Expenses | AU$2.65m |
| Earnings | -AU$1.44m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0076 |
| Gross Margin | 100.00% |
| Net Profit Margin | -119.87% |
| Debt/Equity Ratio | 84.2% |
How did IRX perform over the long term?
See historical performance and comparison